Neuromagen Pharma

Company Overview

Snapshot

Founded in May 2021 by Esther Priel, Neuromagen Pharma operates with 1–10 employees. The company has raised $2.5M across two funding rounds. In May 2022, Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 drug candidate, aimed at slowing the progression of ALS.

Business overview

Neuromagen Pharma is a pharmaceutical company focused on developing a new class of innovative small molecules. Its core technology involves activating telomerase reverse transcriptase (TERT), an enzyme crucial for preventing cellular senescence. The company's mission is to create drugs to delay the onset and progression of neurodegenerative diseases, specifically targeting conditions like ALS, to improve and extend patients' lives. Neuromagen Pharma operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In May 2022, Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 drug candidate for Amyotrophic Lateral Sclerosis (ALS). This designation is a significant regulatory validation, indicating the potential of AGS-499 to address a rare disease with high unmet medical needs. For investors, this signals accelerated development pathways and potential market exclusivity, enhancing the drug's commercial viability and the company's strategic position in neurodegenerative disease therapeutics.

Company Intelligence Q&A

What is Neuromagen Pharma's primary focus?

Neuromagen Pharma is developing novel small molecules designed to activate telomerase reverse transcriptase (TERT) to prevent cellular senescence, with a primary focus on creating drugs to delay the onset and progression of neurodegenerative diseases like ALS.

When was Neuromagen Pharma founded and by whom?

Neuromagen Pharma was founded in May 2021 by Esther Priel.

Has Neuromagen Pharma received any significant regulatory designations?

Yes, in May 2022, Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 drug candidate, which is being developed to slow the progression of Amyotrophic Lateral Sclerosis (ALS).

What was a key funding event for Neuromagen Pharma?

In March 2022, Neuromagen Pharma announced the approval of a NIS 1.8M budget from the Israel Innovation Authority R&D Fund Incentive Program.

What is the total capital raised by Neuromagen Pharma?

Neuromagen Pharma has raised a total of $2.5M across two funding rounds.